These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 19506161)

  • 1. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
    Grimwade D; Jovanovic JV; Hills RK; Nugent EA; Patel Y; Flora R; Diverio D; Jones K; Aslett H; Batson E; Rennie K; Angell R; Clark RE; Solomon E; Lo-Coco F; Wheatley K; Burnett AK
    J Clin Oncol; 2009 Aug; 27(22):3650-8. PubMed ID: 19506161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    Grimwade D; Jovanovic JV; Hills RK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
    Chendamarai E; Balasubramanian P; George B; Viswabandya A; Abraham A; Ahmed R; Alex AA; Ganesan S; Lakshmi KM; Sitaram U; Nair SC; Chandy M; Janet NB; Srivastava VM; Srivastava A; Mathews V
    Blood; 2012 Apr; 119(15):3413-9. PubMed ID: 22374701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
    Zhang L; Cao Z; Zou Y; Ruan M; Li Q; Wang J; Zhu X
    Int J Hematol; 2012 May; 95(5):500-8. PubMed ID: 22407853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
    Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
    Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
    Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
    Ramos Perez JM; Patel KP; Loghavi S; Garcia-Manero G; Borthakur G; Jabbour E; Wierda W; Pierce S; Brandt M; Kornblau S; Kadia T; Daver N; DiNardo CD; Jain N; Yilmaz M; Short N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Rivera D; McCue D; Kantarjian HM; Ravandi F
    Leuk Lymphoma; 2022 Mar; 63(3):672-675. PubMed ID: 34668451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
    Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
    Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia.
    Lo-Coco F; Ammatuna E
    Curr Top Microbiol Immunol; 2007; 313():145-56. PubMed ID: 17217043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
    Reiter A; Lengfelder E; Grimwade D
    Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
    Ramadan SM; Di Veroli A; Camboni A; Breccia M; Iori AP; Aversa F; Cupelli L; Papayannidis C; Bacigalupo A; Arcese W; Lo-Coco F
    Haematologica; 2012 Nov; 97(11):1731-5. PubMed ID: 22689684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.
    Yoon JH; Kim HJ; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    J Hematol Oncol; 2017 Jan; 10(1):30. PubMed ID: 28114959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.